Immune Defect
10
2
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Opioid, HIV and Immune System
Immune Cells in Diabetic Chronic Foot Ulcers
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma
Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors
Nutraceuticals and Functional Foods
Immunology Dysregulation in Lymphadenitis Tuberculosis : An Observational Study Using Patient' Block Paraffins 2019 Until 2021
Immunological Responses in Bovine vs Mechanical Composite Grafts
Immunomodulation Effect of Blood Transfusion
Different Doses of Vitamin D and T Regulatory Cells in Preterm Infants
Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome